Skip to main content
. 2016 May 24;6:26611. doi: 10.1038/srep26611

Figure 6. Genetically engineered miR-34a prodrug significantly suppressed tumor growth in an orthotopic osteosarcoma xenograft tumor mouse model.

Figure 6

(A) Timeline of osteosarcoma cell inoculation and drug treatment. (B) Xenograft tumor growth was significantly (P < 0.001, two-way ANOVA) reduced in mice treated with tRNA/miR-34a than the control tRNA/MSA or vehicle. (C) Visual comparison of the dissected orthotopic tumor tissues. Values are mean ± SD (N = 6 in each group).

HHS Vulnerability Disclosure